Clinical Trials Browser

Phase 3 × Bevacizumab × 90 days × Clear all

NCT00217737 2026-03-18

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Phase 3 Active not recruiting

2,431 enrolled 13 charts

Gastrointestinal

Colonic Neoplasms

NCT00569127 2026-03-18

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Phase 3 Active not recruiting

427 enrolled 17 charts

Neuroendocrine Tumors

NCT01167712 2026-03-18

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3 Active not recruiting

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT02997228 2026-03-18

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT05253651 2026-03-16

MOUNTAINEER-03

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07284849 2026-03-16

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT05862285 2026-03-13

UmbrellaMAX

Phase 3 Recruiting

Neoplasms

NCT06824467 2026-03-13

TroFuse-022

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07216703 2026-03-13

TroFuse-036

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT07318558 2026-03-13

TroFuse-021

Phase 3 Recruiting

Ovarian Neoplasms

NCT05239741 2026-03-10

MK-3475-C66

Phase 3 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT07198074 2026-03-10

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Phase 3 Recruiting

Endometrial Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03847428 2026-03-06

EMERALD-2

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04230187 2026-03-05

TRIBE-C

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06819007 2026-03-05

DO-01

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT06951503 2026-03-04

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Phase 3 Recruiting

Gastrointestinal

Colorectal Adenocarcinoma

NCT00433511 2026-03-03

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Phase 3 Active not recruiting

4,994 enrolled 11 charts

Breast Adenocarcinoma

NCT00588770 2026-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 3 Active not recruiting

403 enrolled 10 charts

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT04094688 2026-03-03

SOLARIS

Phase 3 Active not recruiting

455 enrolled 13 charts

Gastrointestinal

Colorectal Adenocarcinoma

NCT04215731 2026-03-03

FOBEAR

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT07225270 2026-03-03

RAINFOL-04

Phase 3 Recruiting

Ovarian Neoplasms

NCT07228832 2026-03-03

HARMONi-GI3

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05863195 2026-03-02

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06252649 2026-02-27

CodeBreaK 301

Phase 3 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT06888817 2026-02-25

BRAINS

Phase 3 Recruiting

Brain Neoplasms, Glioma, Radiation Injuries

NCT05445778 2026-02-23

GLORIOSA

Phase 3 Recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05171660 2026-02-17

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

Phase 3 Completed

617 enrolled 29 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04712643 2026-01-30

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04854668 2026-01-30

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07222800 2026-01-30

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Phase 3 Recruiting

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Rectal Diseases, Colorectal Neoplasms

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT03778957 2026-01-16

EMERALD-1

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04649489 2026-01-15

TALENTOP

Phase 3 Active not recruiting

Venous Thrombosis

NCT06580314 2026-01-14

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT03148418 2026-01-13

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Phase 3 Active not recruiting

Neoplasms

NCT06921785 2026-01-09

ARTEMIDE-HCC01

Phase 3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05112965 2026-01-07

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

Neoplasms

NCT05904886 2025-12-31

SKYSCRAPER-14

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Active not recruiting

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT06791512 2025-12-24

BASKETⅢ

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms